According to the World Health Organization, cardiovascular disease (CVD) remains the
leading cause of death worldwide, accounting for approximately 18 million deaths per year …

There is extensive evidence supporting the interplay between metabolism and immune
response, that have evolved in close relationship, sharing regulatory molecules and …

Background & Aims There have been many studies of the effects of non-alcoholic fatty liver
disease (NAFLD) and the risk of cardiovascular disease (CVD), but these have produced …

Background & Aims Patients with non-alcoholic fatty liver disease (NAFLD) are at increased
chance for cardiovascular events (CVEs). Severity of liver fibrosis is used to determine …

Importance There are no approved treatments for nonalcoholic fatty liver disease (NAFLD)
despite its association with obesity and increased risk of cardiovascular disease (CVD) …

5′ AMP-activated protein kinase (AMPK) is known as metabolic sensor in mammalian cells
that becomes activated by an increasing adenosine monophosphate (AMP)/adenosine …

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are two
diseases that are common in the general population. To date, many studies have been …

Objective Non-alcoholic fatty liver disease (NAFLD) is an obesity-related condition
associated with cardiovascular mortality. Yet, whether or not NAFLD is independently …

Background Nonalcoholic fatty liver disease (NAFLD) has been linked to an increased risk
of cardiovascular disease (CVD). To explore the impact of diabetes mellitus (DM) as a …

Non-alcoholic fatty liver disease (NAFLD), most common chronic hepatic pathology, that
occurs in the developed countries is estimated at 1/3 of the population. Amongst the …